更新于：2024-06-22

Lutikizumab

更新于：2024-06-22

概要

研发状态

概要

基本信息

药物类型

双特异性抗体

别名

Immunoglobulin, anti-(interleukin 1.beta./interleukin 1.alpha.) (synthetic human a-1234138 heavy chain), disulfide with synthetic human a-1234138 light chain, dimer、lutikizumab、ABT-981

靶点

IL-1α x IL-1β

作用机制

IL-1α抑制剂(白细胞介素-1α抑制剂)、IL-1β抑制剂(白细胞介素-1β抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

序列信息

Sequence Code 9550995H

来源: *****

Sequence Code 9551004L

来源: *****

关联

项与 Lutikizumab 相关的临床试验

NCT06468228 / Not yet recruiting临床3期

A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. This study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with moderate to severe HS .
Lutikizumab is an investigational drug being developed for the treatment of HS. During Period 1 of the study, participants will placed in 1 of 2 groups called treatment arms. There is a 1 in 2 chance that participants will be assigned to placebo. Around 1280 adult and adolescent participants with moderate to severe HS will be enrolled in the study at approximately 275 sites world wide. During Period 2, participants that were part of the lutikizumab treatment arm in Period 1 will be re-randomized to 1 of 2 lutikizumab treatment arms. Participants that were part of the Placebo arm in Period 1 will start Period 2 with an initiation of lutikizumab followed by a re-randomization to 1 of 2 lutikizumab treatment arms.
In Period 1, participants will receive subcutaneous injections of lutikizumab or placebo every week for 16 weeks. In Period 2, participants that were randomized to lutikizumab in Period 1 will receive subcutaneous injections of lutikizumab every week or every other week for 36-weeks. Participants that were randomized to the placebo arm in Period 1 will receive subcutaneous injections of lutikizumab every week for 16 weeks, then either every week or every other week for 20 weeks
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires and diaries.

开始日期2024-07-17

申办/合作机构

AbbVie, Inc.

NCT06257875 / Recruiting临床2期

A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult subjects with UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed.
Lutikizumab is an investigational product being developed for the treatment of UC. Participants are placed in groups called treatment arms. Each group receives a different treatment. In the Induction Period, participants will be randomized into 1 of 3 arms receiving lutikizumab Dose 1, lutikizumab Dose 2, or adalimumab. In the Maintenance Period, participants who responded to lutikizumab will be randomized into 1 of 2 arms of lutikizumab maintenance and participants who responded to adalimumab will continue to receive adalimumab. All participants who did not achieve clinical response per modified Mayo Score at the end of the Induction period will receive open label lutikizumab. Around 200 adult participants with UC will be enrolled at approximately 280 sites worldwide.
In the Induction Period, participants will be randomized to receive intravenous (IV) and subcutaneous (SC) lutikizumab or SC adalimumab for 12 weeks. At the 12 week mark, participants who are on lutikizumab who have responded to treatment will be re-randomized to receive SC lutikizumab at different intervals until Week 52. Participants who are on adalimumab who are responding to treatment will continue to receive adalimumab until Week 52. Participants who do not respond to treatment will receive open-label SC lutikizumab until Week 52.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

开始日期2024-03-23

申办/合作机构

AbbVie, Inc.

NCT06067568 / Completed临床1期

A Phase 1 Study in Healthy Subjects to Evaluate the Relative Bioavailability of Two Lutikizumab Formulations and to Evaluate Lutikizumab Pharmacokinetics, Safety, and Tolerability in Healthy Chinese Subjects

The purpose of this study is to compare the bioavailability of two different formulations of lutikizumab, and to assess adverse events (AEs) and how lutikizumab moves through the body in healthy Chinese participants.

开始日期2023-09-28

申办/合作机构

AbbVie, Inc.

100 项与 Lutikizumab 相关的临床结果

登录后查看更多信息

100 项与 Lutikizumab 相关的转化医学

登录后查看更多信息

100 项与 Lutikizumab 相关的专利（医药）

登录后查看更多信息

项与 Lutikizumab 相关的文献（医药）

2020-11-04·BioMed research international3区 · 生物学

Is Lutikizumab, an Anti–Interleukin-1α/β Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis

3区 · 生物学

ArticleOA

作者: Wu, Ren ; Zhou, Jian ; Aili, Dilihumaer ; Dou, Pengcheng ; Li, Yihan ; Cao, Ziqin ; Jie, Shuo ; Hu, Xuantao ; Li, Yajia ; Long, Zeling ; Wu, Tong ; Wang, Wanchun

Objective. Most guidelines recommend the use of nonsteroidal anti-inflammatory drugs (NSAIDs), duloxetine, and tramadol for the nonoperative treatment of osteoarthritis (OA), but the use of them is limited by the tolerability and safety concerns. Lutikizumab is a novel anti–IL-1α/β dual variable domain immunoglobulin that can simultaneously bind and inhibit IL-1α and IL-1β to relieve the pain and dysfunction symptoms. We conducted this network meta-analysis to comprehensively compare the clinical efficacy and safety of lutikizumab with other drugs recommended by guidelines. Methods. We conducted a Bayesian network and conventional meta-analyses to compare the efficacy and safety of lutikizumab with other traditional drugs. All eligible randomized clinical trials, in PubMed, CNKI, EMBASE, and Web of Science databases, from January 2000 to January 2020, were included. The Cochrane risk of the bias assessment tool was used for quality assessment. Pain relief, function improvement, and risk of adverse effects (AEs) were compared in this study. Results. 24 articles with 11858 patients were included. Duloxetine (DUL) had the largest effect for pain relief (4.76, 95% CI [2.35 to 7.17]), and selective cox-2 inhibitors (SCI) were the most efficacious treatment for physical function improvement (SMD 3.94, 95% CI [2.48 to 5.40]). Lutikizumab showed no benefit compared with placebo for both pain relief (SMD 1.11, 95% CI [-2.29 to 4.52]) and function improvement (SMD 0.992, 95% CI [-0.433 to 4.25]). Lutikizumab and all other drugs are of favorable tolerance for patients in the treatment of OA compared with placebo. Conclusions. Lutikizumab, the new anti–Interleukin-1α/β dual variable domain immunoglobulin, showed no improvement in pain or function when compared with placebo. Selective cox-2 inhibitors and duloxetine remain the most effective and safest treatment for OA. More high-quality trials are still needed to reconfirm the findings of this study.

2020-07-01·Annals of the rheumatic diseases

Can IL-1 be used as a target for osteoarthritis?

Letter

作者: Tian, Jian ; Zhang, Fangjie ; Cheng, Chao

We read with deep interest the article by Kloppenburg et al ,1 which was aimed at assessing the efficacy, safety, pharmacokinetics and pharmacodynamics of anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab (ABT-981) in erosive hand osteoarthritis (HOA). The results indicated that administration of 200 mg lutikizumab subcutaneously every 2 weeks for 24 weeks did not improve pain or imaging outcomes in erosive HOA compared with a placebo. This conclusion might be disappointing for doctors and even patients who desire a wider choice in drugs. In this study, the authors administered lutikizumab to neutralise the expression of IL-1α and IL-1β; however, to the best of our knowledge, until recently, the source …

2020-07-01·Annals of the rheumatic diseases1区 · 医学

Response to: ‘Can IL-1 be used as a target for osteoarthritis?’ by Cheng et al

1区 · 医学

Article

作者: Kloppenburg, Margreet ; Levesque, Marc

We thank Cheng, Tian and Zhang1 for their interest in our article2 that showed that targeting interleukin (IL)-1α and IL-1β with lutikizumab did not significantly improve clinical and imaging outcomes in patients with inflammatory erosive hand osteoarthritis (HOA). The results of the study were indeed disappointing and, appropriately, should stimulate discussion about the role of IL-1 in osteoarthritis. In our trial, levels of IL-1 were significantly reduced in subjects with erosive HOA and moderate to severe inflammation indicated by joint swelling, joint pain and synovitis.1 Although levels of IL-1 were not measured after week 4 of treatment, other biomarkers (eg, …

项与 Lutikizumab 相关的新闻（医药）

2024-06-21

·医药笔记

艾伯维：IL-1α/β抗体启动化脓性汗腺炎三期临床

▎Armstrong 2024年6月21日，艾伯维在Clinicaltrials.gov网站上注册了IL-1α/β抗体Lutikizumab治疗化脓性汗腺炎的三期临床试验。该三期临床计划入组1280例化脓性汗腺炎患者，预计2026年底完成。今年1月，艾伯维公布了Lutikizumab治疗化脓性汗腺炎的二期临床优异数据。总结 Kiniksa的IL-1α/β抑制剂Arcalyst在美国已经获批上市，用于治疗吡啉相关的周期性综合征（CAPS）、IL-1受体拮抗剂缺乏症（DIRA）。华东医药于2022年2月引进该产品的亚太地区权益（包括中国、韩国和澳大利亚和其他18个国家，但不包括日本）。 Armstrong技术全梳理系列 GPRC5D靶点全梳理； CD40靶点全梳理； CD47靶点全梳理；补体靶向药物技术全梳理；补体药物：眼科治疗的重要方向； Claudin 6靶点全梳理； Claudin 18.2靶点全梳理；靶点冷暖，行业自知；中国大分子新药研发格局；被炮轰的“me too”；佐剂百年史；胰岛素百年传奇； CUSBEA：风雨四十载；中国新药研发的焦虑；中国生物医药企业的研发竞争；中国双抗竞争格局；中国ADC竞争格局；中国双抗技术全梳理；中国ADC技术全梳理； Ambrx技术全梳理； Vir Biotech技术全梳理； Immune-Onc技术全梳理；亘喜生物技术全梳理；康哲药业技术全梳理；科济药业技术全梳理；恺佧生物技术全梳理；同宜医药技术全梳理；百奥赛图技术全梳理；腾盛博药技术全梳理；创胜集团技术全梳理；永泰生物技术全梳理；中国抗体技术全梳理；德琪医药技术全梳理；德琪医药技术全梳理2.0；和铂医药技术全梳理；荣昌生物技术全梳理；再鼎医药技术全梳理；药明生物技术全梳理；恒瑞医药技术全梳理；豪森药业技术全梳理；正大天晴技术全梳理；吉凯基因技术全梳理；基石药业技术全梳理；百济神州技术全梳理；百济神州技术全梳理第2版；信达生物技术全梳理；信达生物技术全梳理第2版；中山康方技术全梳理；复宏汉霖技术全梳理；先声药业技术全梳理；君实生物技术全梳理；嘉和生物技术全梳理；志道生物技术全梳理；道尔生物技术全梳理；尚健生物技术全梳理；康宁杰瑞技术全梳理；科望医药技术全梳理；科望医药技术全梳理2.0；岸迈生物技术全梳理；礼进生物技术全梳理；康桥资本技术全梳理；余国良的抗体药布局；荃信生物技术全梳理；安源医药技术全梳理；三生国健技术全梳理；仁会生物技术全梳理；乐普生物技术全梳理；同润生物技术全梳理；宜明昂科技术全梳理；派格生物技术全梳理；迈威生物技术全梳理； Momenta技术全梳理； NGM技术全梳理；普米斯生物技术全梳理；普米斯生物技术全梳理2.0；三叶草生物技术全梳理；贝达药业抗体药全梳理；泽璟制药抗体药全梳理；恒瑞医药抗体药全梳理；齐鲁制药抗体药全梳理；石药集团抗体药全梳理；豪森药业抗体药全梳理；华海药业抗体药全梳理；科伦药业抗体药全梳理；百奥泰技术全梳理；凡恩世技术全梳理。

临床3期抗体药物偶联物临床2期

2024-03-29

·E药经理人

王者解码！艾伯维如何变身千亿免疫赛道的“六边形战士”

尽管在千亿美元免疫赛道持续领跑于一众竞争对手，龙头地位无人能撼动，但“免疫王者”艾伯维仍然没有懈怠——持续打造免疫领域“冠军选手”，在赢取免疫赛场“大满贯”征途中，仍不断培养“冠军选手”或“归化”“种子选手”。艾伯维俨然已经成为免疫赛道的“六边形战士”，多维防御竞争对手发起的一波又一波的挑战。就在3月25日，艾伯维宣布和Landos Biopharma签订最终协议，艾伯维将潜在斥资超过2亿美元收购Landos——一家专注为自身免疫性疾病患者开发口服疗法的临床阶段的生物公司。Landos的主打项目NX-13是一款潜在“first-in-class”口服NLRX1激动剂，旨在治疗溃疡性结肠炎（UC），目前已进入临床2期阶段。这也是新年伊始，艾伯维在免疫领域的第二个大动作。而1个月前的2月28日，艾伯维和免疫治疗公司OSE Immunotherapeutics 宣布达成战略合作伙伴关系，共同开发 OSE-230──一种旨在解决严重慢性炎症性疾病的单克隆抗体。与此同时，刚刚结束的2024美国皮肤科学会年会和2024欧洲克罗恩病和结肠炎组织年会上，艾伯维也有大动作——公布了乌帕替尼在皮科和消化领域的研究进展，均引人瞩目。频频出手的艾伯维，再度吸引了业内的目光。作为免疫赛道的“六边形战士”，艾伯维如同乒乓赛场的中国队，一直以擅长培育“冠军选手”著称，不仅拥有“冠军选手”修美乐、还有“种子选手”Skyrizi和乌帕替尼，共同“征战”免疫领域不同赛场赢取“大满贯”，同时在“梯队建设”上，也不断完善“后备人才”方阵。竞争对手短时间内要威胁艾伯维的免疫王者位置实在不易。01“冠军选手”接力从修美乐，到“双子星”Skyrizi和乌帕替尼，艾伯维在培养“冠军选手”和“种子选手”的能力上，一直为业界瞩目。2023年，艾伯维的3款自免产品均进入免疫赛道产品销量前十，也是唯一一家3款免疫产品全部进入销量前十的药企。其中，已蝉联11年“药王”的修美乐以144.04亿美元的销量，再度问鼎2023免疫赛道药王。“种子选手”Skyrizi和乌帕替尼分别以77.63亿美元和39.69亿美元，分列免疫赛道产品销量的第四和第七位。一方面，艾伯维通过持续对修美乐进行创新挖潜，把修美乐这一“药王”级的创新药价值做到极致的；另一方面，艾伯维着力打造具有接棒修美乐能力的“种子选手”，无论是自己“培养”的选手乌帕替尼，还是“归化”选手Skyrizi，均成长速度惊人，已可独挡一面。Skyrizi和乌帕替尼已连续8个季度增长超过50%，从2019年时候的两者合计收入4亿美元，迅速增长至2023年的合计117亿美元。根据Evaluate Pharma的最新预测，2024年Skyrizi销量将接近100亿美元，有望成为艾伯维培育的第二个百亿“药王”。艾伯维预计两者2027年合计收入将达到270亿美元，为艾伯维继续在免疫赛道驰骋提供了充足的动力。虽然其他头部药企不乏自家的“优秀选手”，也不断发起对艾伯维免疫王者地位一波又一波的挑战。然而，从整体表现来看，艾伯维去年凭借整体优势，轻松赢下了王者之战——其免疫管线营收261.36亿美元，比排名第二的强生高出80多亿美元，并远远超过排在第三和第四位的赛诺菲和诺华的营收总和。02免疫赛场“大满贯”在免疫赛场，艾伯维一直展示着自己的统治力。从TNF-α到白介素抑制剂、JAK抑制剂，从皮科到消化、免疫等不同子领域，布局于不同靶点的3个“冠军选手”和“种子选手”，让艾伯维在“大满贯”的路上，一路生花。在TNF-α抑制剂中，艾伯维的修美乐一直占据第一把交椅，涵盖三大主流自身免疫疾病领域多个适应症，包括类风湿关节炎、银屑病关节炎、强直性脊柱炎、克罗恩病、溃疡性结肠炎等。这个初代“冠军选手”，在20年时间里，为艾伯维带来的收入累计超过2000亿美元。乌帕替尼是一款每日口服一次的JAK1选择性小分子抑制剂，艾伯维将其视为修美乐的继任者之一。乌帕替尼也不负众望，在美国和中国一举拿下7个适应症。除去适应症的拓展，艾伯维也一直在深挖乌帕替尼的潜力。在2024美国皮肤科学会年会和2024欧洲克罗恩病和结肠炎组织年会上，艾伯维分别公布了乌帕替尼在相关领域的最新进展，无不体现出“种子选手”的实力。另一款“种子选手”Skyrizi是一种白细胞介素-23(IL-23)抑制剂。目前，Skyrizi已有斑块型银屑病、银屑病关节炎和克罗恩病3个适应症在美国获批。Skyrizi也有望被引入中国。在一场与乌司奴单抗的PK中（克罗恩病患者中的头对头研究），无论是在临床缓解，还是内镜缓解率上，Skyrizi都赢得了更好的表现。03完备的“梯队建设”凭借初代“冠军选手”打下的江山，艾伯维不断培养出接棒的“种子选手”，在免疫赛场上不断荣誉加身。不过这些并没有让艾伯维沉浸在过去的成绩里，如何赢得未来，才是艾伯维考虑的。有着完备的体系和底蕴，在培养“后备力量”上，艾伯维显然得心应手。艾伯维两款完全自研的免疫学产品Lutikizumab和ABBV-668均已进入2期临床。在今年1月，Lutikizumab治疗成人中重度化脓性汗腺炎的2期临床取得积极结果，基于此，艾伯维进一步将Lutikizumab推进到3期临床。ABBV-668是艾伯维开发的苏氨酸蛋白激酶（RIPK）抑制剂，2期临床也有望在明后两年内完成。除了自己培养，凭借多年赛道深耕的阅历和眼光，艾伯维也在不断“归化”“种子选手”，撬动高价值产品，从而重塑和巩固自身实力，比如最成功的“归化选手”Skyrizi。就在本周，艾伯维和Landos Biopharma达成协议，艾伯维潜在斥资超过2亿美元收购Landos。其主打产品NX-13是一款潜在“first-in-class”口服NLRX1激动剂。收购完成后，艾伯维将获得更多治疗免疫系统相关疾病的药物，有望进一步扩充其“种子选手”阵营。此外，今年年初，艾伯维接连宣布与OSE Immunotherapeutics和Tentarix Biotherapeutics达成合作。与OSE Immunotherapeutics的合作，让艾伯维获得了一款严重慢性炎症性疾病在研新药OSE-230的开发、生产以及商业化全球独家许可权利。与Tentarix biotheraptics的合作，将把艾伯维在肿瘤学和免疫学方面的专业知识与Tentarix的专有Tentacles平台相结合。虽然千亿美元免疫赛道强者众多，目前处在一个新老交替、列强纷争的时代。但凭借“冠军选手”和“种子选手”的表现，艾伯维在免疫赛场的统治力仍将持续。艾伯维已然认识到“梯队建设”的重要性，从自研创新到收购引入，艾伯维早已布局未来“新生力量”，将六维雷达图边框“拉满”，“六边形战士”的统治地位难以被撼动。

并购临床2期免疫疗法

2024-03-29

·BioSpace

Avalo Snags Former Eli Lilly Asset and $185M in Major Pipeline Pivot

Pictured: Close-up of a skin lesion in a patient with hidradenitis suppurativa/iStock, krblokhin Avalo Therapeutics made a significant strategic pipeline decision Wednesday, acquiring AlmataBio and focusing on the biotech’s ex-Eli Lilly hidradenitis suppurativa candidate over its existing assets. Prior to the deal, Avalo was advancing a pipeline led by an inflammatory bowel disease drug candidate. Quisovalimab, an anti-LIGHT antibody, and an BTLA agonist fusion protein remain part of Avalo’s pipeline but are now listed as “under strategic review.” The focus is on getting the acquired anti-IL-1β antibody AVTX-009 to a Phase II readout in the chronic skin condition hidradenitis suppurativa (HS). Investors have stepped up to bankroll Avalo’s goal of reporting topline results in the indication in 2026. Commodore Capital and TCGX co-led a private placement in the biotech with assists from BVF Partners, Deep Track Capital, OrbiMed, Petrichor and RA Capital Management. The placement is worth up to $185 million, $115.6 million of which the investors are providing upfront. “We believe that HS is a multi-billion-dollar commercial opportunity and that AVTX-009 has the potential to be best-in-class and best-in-indication because of its target, half-life and potency, which may allow for strong efficacy and convenient dosing,” Avalo CEO Garry Neil said in a statement. Avalo expects the upfront money to fund its operations into 2027. As such, the money will enable the biotech to show how AVTX-009 performs in HS in a Phase II trial. Avalo contends the molecule has a high probability of success in the indication. That belief is based on data generated by other developers of IL-1β drug candidates. AbbVie is running a Phase II clinical trial of the anti-IL-1α/β antibody lutikizumab in patients with HS. The drugmaker published data from the study and committed to further development early in 2024. While AbbVie’s success partly derisks AVTX-009, it also means Avalo is up against a leading drugmaker that has advanced deeper into the clinic. Avalo’s asset is different from lutikizumab in that it only targets IL-1β. As Avalo has said, clinical evidence suggests anti-IL-1α therapy is not effective in HS. The evidence comes from a Johnson & Johnson candidate that failed a Phase II clinical trial. Eli Lilly originally developed AVTX-009 but then offloaded the asset to AlmataBio. Avalo is taking control of the molecule by paying AlmataBio shareholders $15 million in stock and $7.5 million in cash. The deal also includes a $5 million milestone payment tied to the dosing of the first patient in Phase II. Avalo will pay a further $15 million when it doses the first patient in a Phase III trial. Nick Paul Taylor is a freelance pharmaceutical and biotech writer based in London. He can be reached on LinkedIn.

临床2期并购临床1期临床3期临床失败

100 项与 Lutikizumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16224

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
化脓性汗腺炎	临床3期	-	AbbVie, Inc.	2024-07-17
溃疡性结肠炎	临床2期	美国	AbbVie, Inc.	2024-03-23
溃疡性结肠炎	临床2期	日本	AbbVie, Inc.	2024-03-23
肿瘤	临床2期	美国	AbbVie, Inc.	2021-12-28
肿瘤	临床2期	日本	AbbVie, Inc.	2021-12-28
肿瘤	临床2期	澳大利亚	AbbVie, Inc.	2021-12-28
肿瘤	临床2期	加拿大	AbbVie, Inc.	2021-12-28
肿瘤	临床2期	德国	AbbVie, Inc.	2021-12-28
肿瘤	临床2期	希腊	AbbVie, Inc.	2021-12-28
肿瘤	临床2期	波多黎各	AbbVie, Inc.	2021-12-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05139602 (Biospace) 人工标引	临床2期	化脓性汗腺炎	153	lutikizumab	廠遞觸蓋積壓繭襯窪壓(壓鏇鹹積醖衊壓廠選壓) = 衊鏇構顧鏇簾製獵蓋網範鑰顧鹽選觸鹹築獵觸 (艱鬱糧築鑰襯糧夢艱獵 ) 更多	积极	2024-01-08
				placebo	鬱觸範鏇餘鹹獵選簾鬱(醖鹹淵製製繭衊廠艱蓋) = 淵遞製膚鏇積鬱憲蓋顧願壓餘窪壓觸選鑰製衊 (繭襯鏇顧獵網鹽憲選積 ) 更多
NCT02087904 (CTgov)	临床2期	膝关节炎	350	Placebo	顧壓願餘鏇鏇艱糧鹹積(蓋醖範築範顧製選鏇齋) = 艱網觸積獵鬱鏇糧夢襯範獵夢繭簾網製淵範觸 (醖鏇製鏇製膚構衊憲顧, 齋蓋顧獵淵餘簾獵淵齋 ~ 夢餘簾鑰顧醖夢壓衊醖) 更多	-	2019-08-28
NCT01668511 (Pubmed \| Osteoarthritis Cartilage)	临床1期	膝关节炎	36	ABT-981 0.3 mg/kg	鹹鬱築遞範膚衊獵遞淵(鹽簾齋遞醖壓餘餘遞衊) = 鏇壓醖窪廠製簾齋觸構鑰製網鹽積壓淵繭鑰觸 (餘選壓餘鑰淵製艱廠醖 ) 更多	-	2017-12-01
				ABT-981 1 mg/kg	鹹鬱築遞範膚衊獵遞淵(鹽簾齋遞醖壓餘餘遞衊) = 襯鹽網繭鏇顧鏇獵醖膚鑰製網鹽積壓淵繭鑰觸 (餘選壓餘鑰淵製艱廠醖 ) 更多
NCT02384538 (CTgov)	临床2期	骨关节炎	132	Placebo for ABT-981 (Placebo)	築憲獵繭糧窪淵糧構鹽(糧鬱顧構廠憲衊衊網壓) = 艱窪構憲蓋醖範憲範築獵願醖廠齋淵鏇簾衊憲 (廠選壓醖簾鹹範醖膚膚, 鹽網鹹築鏇築齋廠鏇壓 ~ 積糧鹹膚積壓壓選鹽顧) 更多	-	2017-07-13
				ABT-981 (ABT-981)	築憲獵繭糧窪淵糧構鹽(糧鬱顧構廠憲衊衊網壓) = 繭糧鑰遞壓構壓顧壓願獵願醖廠齋淵鏇簾衊憲 (廠選壓醖簾鹹範醖膚膚, 鹽膚鏇觸網艱鏇積構淵 ~ 繭鹽齋鹹鹹鏇範醖夢壓) 更多
EULAR2014	临床1期	骨关节炎	-	ABT-981	鬱餘鹽鬱餘鹹觸淵鹹廠(鏇選憲遞鑰蓋鏇鬱醖顧) = Measurable ADA titers were detected in 7 subjects on active treatment 繭襯壓網壓膚範獵網襯 (窪蓋繭淵齋夢淵艱窪齋 ) 更多	-	2014-06-11